Crystal Pharmaceutical is lined up to copy 1 of the blockbuster drugs on this tracker, which earned $7.7B combined in 2025.
| Drug | Brand owner | Copy | US LOE | Crystal Pharmaceutical's stage | 2025 brand sales |
|---|---|---|---|---|---|
| Entresto | Novartis | Generic | 2025 | Approved May 2024 | $7.7B |
Each drug page lists sources for these entries. Brand sales show the size of the market, not Crystal Pharmaceutical's share of it.